MedTrace Logo

Emp-Activity: Empagliflozin Functional Capacity

NCT05350202 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3431

Last updated 2025-08-26

Study results available
· View outcomes & findings →

Summary

This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive first prescription of empagliflozin as routine therapy for HF, the other cohort will receive HF therapy with drugs with another mechanism of action. Treatment of HF according to routine practice is determined by the physician independent of the participation of the patient in this non-interventional study.

Conditions

Interventions

DRUG

Empagliflozin

Empagliflozin was administered according to the approved product information.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-18
Primary Completion
2024-07-25
Completion
2024-07-25

Countries

  • Bulgaria
  • Czechia
  • Hungary
  • Poland
  • Romania
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05350202 on ClinicalTrials.gov